Record your personal health story
“Medical records are often incomprehensible to the layperson,” says Nhumi Co-Founder André Elisseeff, PhD. “With Healthcorpus.com, individuals can easily manage their personal health status, stay current on pertinent issues and share information in confidence with family, friends and physicians — in English, French or German.” The official launch will be November 6 at Health 2.0 Europe in Berlin.
Unlike other online PHRs, Nhumi’s virtual model of the human anatomy lets you click your mouse to graphically indicate where it hurts or treatment was applied—or learn more about your anatomy. Users tag free text with 3D coordinates recorded on a virtual model of the human anatomy by simply clicking on the body, creating a pin, then dragging the pin to their text. This in turn enables tagging of medical information with spatial data and direct discovery of health stories from the virtual body.
“It’s that simple,” says Elisseeff, “and the potential for improving personal health is boundless. “Registration is free for this beta release; a mobile version and greater storage capacity are in development.”
Lausanne physician Philip Siegenthaler, MD, says healthcorpus.com let’s him quickly show patients pictures of the human anatomy to explain symptoms, and enables his patients to easily record how they feel and better describe ailments.
“The iPhone was a major advance in terms of making mobile phones more intuitive and fun to use. Nhumi , a carrier of CTI-startup-label, does the same for PHRs. Their flexible and powerful solution seamlessly organizes and visualizes medical data in a uniquely comprehensible and meaningful manner.”
Swiss start-up turns to the Nasdaq
Last year Auris Medical raised more than CHF47 million in venture capital for further growth. This was the largest round of financing in Switzerland in 2013. The company has two drugs in development: an injection for tinnitus and a drug for hearing loss in the inner ear. The tinnitus medication has already started the third and most expensive stage of development, the phase III trial. The Basel company, which has its headquarters in Zug, intends to raise the necessary capital on the Nasdaq: the IPO should bring Auris a total of $95 million in new money.